{"protocolSection": {"identificationModule": {"nctId": "NCT02467387", "nctIdAliases": ["NCT02123706"], "orgStudyIdInfo": {"id": "STEM-104-M-CHF"}, "organization": {"fullName": "CardioCell LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure", "officialTitle": "A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2019-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-05-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-05-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-06-02", "studyFirstSubmitQcDate": "2015-06-09", "studyFirstPostDateStruct": {"date": "2015-06-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-10-25", "resultsFirstSubmitQcDate": "2020-01-06", "resultsFirstPostDateStruct": {"date": "2020-01-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-01-06", "lastUpdatePostDateStruct": {"date": "2020-01-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "CardioCell LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Stemedica Cell Technologies, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.", "detailedDescription": "A phase IIa, single-blind, placebo-controlled, crossover, multi-center, randomized study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of ischemia-tolerant allogeneic mesenchymal bone marrow cells to subjects with heart failure of non-ischemic etiology."}, "conditionsModule": {"conditions": ["Non-Ischemic Heart Failure"], "keywords": ["Non-ischemic Heart Failure", "Stem Cells"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 23, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Experimental: Human (aMBMC)", "type": "EXPERIMENTAL", "description": "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.", "interventionNames": ["Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)"]}, {"label": "Placebo:Lactated Ringer's Solution (LRS)", "type": "PLACEBO_COMPARATOR", "description": "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.", "interventionNames": ["Drug: Lactated Ringer's Solution"]}], "interventions": [{"type": "DRUG", "name": "Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)", "description": "One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.", "armGroupLabels": ["Experimental: Human (aMBMC)"], "otherNames": ["Mesenchymal Stem Cells, (MSC) Marrow Stromal Cells."]}, {"type": "DRUG", "name": "Lactated Ringer's Solution", "description": "One time infusion 1.5mL/kg", "armGroupLabels": ["Placebo:Lactated Ringer's Solution (LRS)"], "otherNames": ["(LRS)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Safety Will be Evaluated by Number of AE", "description": "As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs", "timeFrame": "Total AEs and SAEs within 450 days post-infusion"}], "secondaryOutcomes": [{"measure": "Change in LVEF From Baseline to Day 90 Post-initial Infusion.", "description": "The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point.", "timeFrame": "Baseline to Day 90"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Males and females \u226518 years of age\n2. LVEF \u226435% on echocardiogram within 12 months of randomization to undergo MRI\n3. Screening cardiac MRI at baseline with:\n\n   Ejection fraction \u226440% No significant hyper enhancement on MRI scan in the opinion of the central imaging lab reviewer\n4. Patients with non-ischemic heart failure etiology, as documented by absent or non-obstructive coronary artery disease on x-ray angiography or coronary computed tomography\n5. Patients with history of heart failure and treated for at least three months with GDMT\n6. NYHA class II-III symptoms\n7. Ability to understand and provide signed informed consent\n8. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits\n\nExclusion Criteria:\n\n1. Pregnant or nursing women or those of childbearing age and not using an effective method of contraception\n2. History of stroke within 3 months\n3. Cardiac surgery within 3 months prior to randomization or the likelihood of a requirement for such procedures during the study period\n4. Current ICD or CRT or implantation planned within 6 months of infusion\n5. Presence of clinically significant, uncorrected valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension\n6. History of cardiac arrest or life-threatening arrhythmias within 3 months\n7. Treatment with parenteral inotropic agents within 1 month of randomization\n8. Anticipated cardiac transplantation within 1 year\n9. Illness other than heart failure with life expectancy less than 1 year\n10. Received an experimental drug or device within 30 days of randomization\n11. Left ventricular assist device or implantation planned in the next 6 months\n12. Patients with complex congenital heart disease\n13. Uncontrolled seizure disorder\n14. Presence of immune deficiency\n15. Clinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests:\n\n    * Liver disease = ALT or AST \\> 3x normal, alkaline phosphatase or bilirubin \\>2x normal)\n    * Renal disease = estimated glomerular filtration rate as assessed by the MDRD formula \\<30 ml/min\n    * Hematologic = Unexplained leukocytosis \\>10 or hemoglobin \\< 9gm/dl\n16. Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor for which participation in the study would pose a safety risk to the subject\n17. Inability to comply with the conditions of the protocol\n18. Malignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix\n19. Active myocarditis or early postpartum cardiomyopathy (within six months).\n20. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment\n21. Porphyria\n22. Allergy to sodium citrate or any \"caine\" type of local anesthetic\n23. Any contraindication for gadolinium use for MRI\n24. Patient scheduled for hospice care\n25. Clinically relevant abnormal findings in the clinical history, physical examination, ECG, or laboratory tests at the screening assessment that would interfere with the objectives of the study or would preclude safe completion of the study. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury\n26. Any other medical, social, or geographical factor that would make it unlikely that the patient could comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or noncompliance)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kristrun Stardal, RN, BSN", "affiliation": "Clinical Operations Manager", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "MedStar Washington Hospital Center", "city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Emory University Hospital", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Northwestern University Centers for Heart Failure Therapy", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Stony Brook Heart Institute", "city": "Stony Brook", "state": "New York", "zip": "11794", "country": "United States", "geoPoint": {"lat": 40.92565, "lon": -73.14094}}, {"facility": "Hospital of the University of Pennsylvania, Heart Failure and Transplant Program", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}]}, "referencesModule": {"references": [{"pmid": "27856497", "type": "DERIVED", "citation": "Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. Circ Res. 2017 Jan 20;120(2):332-340. doi: 10.1161/CIRCRESAHA.116.309717. Epub 2016 Nov 16."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "23 out of 34 patients have been randomized and 22 received the study intervention. Of those not randomized, 10 did not meet inclusion criteria and 1 could not tolerate CMR.", "recruitmentDetails": "34 patients have been screened for eligibility between June, 2014 and April, 2016 at Emory University Medical Center, Atlanta, GA, Northwestern University Medical Center, Chicago, IL, University of Pennsylvania Medical Center, Philadelphia, PA, and Stony Brook University Medical Center, Stony Brook, NY.", "groups": [{"id": "FG000", "title": "itMSC, Then Placebo", "description": "Participants first received itMSC 1.5 million per kilogram of weight, infused in the corresponding hospital facility at speed of 1 mL/minute (cell concentration 1 million/mL). After 90 days patients completed treatment at 90 days, and thus constituted the control treatment. After 90 day follow-up testing patients received Placebo and followed up for another 90 days. Total efficacy follow-up - 180 days. Safety measurements 0, 60, 90, days 270 and 450."}, {"id": "FG001", "title": "Placebo, Then itMSC", "description": "Participants first received Placebo, infused in the corresponding hospital facility at speed of 1 mL/minute. After 90 days patients completed Placebo Control and related testing, and received itMSC treatment 1.5 million per kilogram of weight, and thus constituted the itMSC treated group for another 90 days.Total efficacy follow-up - 180 days. Safety measurements 0, 60, 90, days 270 and 450."}], "periods": [{"title": "First Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Received Treatment as Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Second Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Study Population", "description": "itMSC, then Placebo: Participants first received itMSC 1.5 million per kilogram of weight, infused in the corresponding hospital facility at speed of 1 mL/minute (cell concentration 1 million/mL). After 90 days patients completed treatment at 90 days, and thus constituted the control treatment. After 90 day follow-up testing patients received Placebo and followed up for another 90 days. Total efficacy follow-up - 180 days. Safety follow-up - 240 days.\n\nPlacebo, then itMSC: Participants first received Placebo, infused in the corresponding hospital facility at speed of 1 mL/minute. After 90 days patients completed Placebo Control and related testing, and received itMSC treatment 1.5 million per kilogram of weight, and thus constituted the itMSC treated group for another 90 days.Total efficacy follow-up - 180 days. Safety follow-up - 240 days. and thus constituted the control treatment."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "22"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.3", "spread": "12.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "15"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "92.5", "spread": "19.96"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.24", "spread": "7.56"}]}]}]}, {"title": "New York Heart Association (NYHA) Class", "description": "NYHA Class:\n\nClass I (Mild): Patients with cardiac disease but without resulting in limitation of physical activity.\n\nClass II (Mild): Cardiac disease resulting in slight limitation of physical activity.\n\nClass III (Moderate): Cardiac disease resulting in marked limitation of physical activity.\n\nClass IV (Severe): Cardiac disease resulting in the inability to carry on any physical activity without discomfort.\n\nImprovement in NYHA classification was analyzed using logistic regression with treatment and group assignment (itMSC - placebo vs. placebo - itMSC) as covariates.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Class II", "measurements": [{"groupId": "BG000", "value": "21"}]}, {"title": "Class III", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "120", "spread": "17.1"}]}]}]}, {"title": "Diastolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74", "spread": "9.6"}]}]}]}, {"title": "Heart Rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "bpm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78", "spread": "14.2"}]}]}]}, {"title": "N-terminlal-proB-type Natriuretic Peptide (NT-proBNP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "212", "spread": "841"}]}]}]}, {"title": "Troponin I", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ug/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.0009", "spread": "0.0003"}]}]}]}, {"title": "Serum Sodium", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "138", "spread": "2"}]}]}]}, {"title": "Serum Creatinine", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.96", "spread": "0.23"}]}]}]}, {"title": "Aspartate Aminotransferase (AST)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "International Units/milliliter (IU/mL)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21.86", "spread": "8.64"}]}]}]}, {"title": "Alanine Aminotransferase (ALT)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "IU/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21.82", "spread": "9.57"}]}]}]}, {"title": "Total bilirubin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.8", "spread": "0.4"}]}]}]}, {"title": "Albumin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.2", "spread": "0.36"}]}]}]}, {"title": "History of Hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "History of Diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "History of Atrial Fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "History of Kidney Disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Left Ventricular Ejection Fraction (LVEF)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.6", "spread": "9.8"}]}]}]}, {"title": "Left Ventricular End Systolic Volume (LVESV)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "189.6", "spread": "114.2"}]}]}]}, {"title": "Left Ventricular End-Diastolic Volume (LVEDV)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "264.9", "spread": "120.4"}]}]}]}, {"title": "Loop diuretic medication", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16"}]}]}]}, {"title": "angiotensin converting enzyme inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB) medication", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}]}, {"title": "Mineralocorticoid Receptor Antagonist medication", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}]}, {"title": "Beta-blocker", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Safety Will be Evaluated by Number of AE", "description": "As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs", "populationDescription": "All 22 participants that received itMSC treatment were included. All adverse events are divided into serious and non-serious.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of events", "timeFrame": "Total AEs and SAEs within 450 days post-infusion", "groups": [{"id": "OG000", "title": "Experimental", "description": "Participants received itMSC"}, {"id": "OG001", "title": "Placebo", "description": "Participants received Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Cell related adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "All-cause hospitalization", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "All-cause death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change in LVEF From Baseline to Day 90 Post-initial Infusion.", "description": "The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point.", "populationDescription": "The secondary efficacy endpoint according to the protocol was the change in LVEF from baseline to Day 90 post-initial infusion.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of ejection volume", "timeFrame": "Baseline to Day 90", "groups": [{"id": "OG000", "title": "Experimental: Human (itMSC)", "description": "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.\n\nAllogeneic Mesenchymal Bone Marrow Cells (itMSC): One time infusion Allogeneic Mesenchymal Bone Marrow Cells (itMSC) 1.5 million cells/kg."}, {"id": "OG001", "title": "Placebo:Lactated Ringer's Solution (LRS)", "description": "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.\n\nLactated Ringer's Solution: One time infusion 1.5mL/kg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "Baseline (%)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "34.3", "spread": "7.91"}, {"groupId": "OG001", "value": "34.5", "spread": "7.49"}]}]}, {"title": "90 days (%)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "34.1", "spread": "9.7"}, {"groupId": "OG001", "value": "36.7", "spread": "5.42"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "450 days", "description": "All AE summaries were restricted to treatment-emergent adverse events (TEAEs), and TEAEs were defined as those AEs with onset after the first dose of study treatment or existing events that worsened after the first dose during the study.\n\nTreatment-emergent AEs by severity (severe, other), relationship to study treatment (\"related\" or \"not related\"). Reported treshold 5%.", "eventGroups": [{"id": "EG000", "title": "Experimental", "description": "Subjects that received experimental drug, 22 subjects", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 1, "seriousNumAtRisk": 22, "otherNumAffected": 18, "otherNumAtRisk": 22}, {"id": "EG001", "title": "Placebo", "description": "Subjects that received placebo, 20 subjects", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 15, "otherNumAtRisk": 20}], "seriousEvents": [{"term": "atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}], "otherEvents": [{"term": "General Disorders and administration site condition: chest pain, fatigue, pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 20}]}, {"term": "Venous Pressure Jugular Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 20}]}, {"term": "Upper Respiratory Tract, Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 20}]}, {"term": "Fluid Overload, Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 20}]}, {"term": "Dizziness, headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 20}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Sergey Sikora, President and CEO", "organization": "CardioCell, LLC", "email": "SSIKORA@STEMCARDIOCELL.COM", "phone": "760-315-0861"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2014-02-19", "uploadDate": "2019-11-14T16:47", "filename": "Prot_SAP_000.pdf", "size": 843990}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}